Pyrotinib in combination with Capecitabine

Phase 3

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR (JHPCY)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

JHPCYPhase 3$38.2B

SHR-A1811 Phase 3 Est. Readout

Pyrotinib in combination with Capecitabine• HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane381

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

View Full Landscape

Drug Information

Target Indication

HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Clinical Trial

NCT05424835

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

JHPCY

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

Biotechnology•North America•NASDAQ

Related Pipeline

JSKN003Phase 3

Advanced Solid Tumor

Irinotecan liposome、5-Fluorouracil、LeucovorinPhase 3

Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy

X0002 SprayPhase 3

KNEE OSTEOARTHRITIS

RocuroniumPhase 3

Neuromuscular Blockade

HRS-9190Phase 3

Neuromuscular Blockade

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts